Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate

INTRODUCTION: Only limited information is available on cost efficacy of the various biological agents used to treat patients with rheumatoid arthritis with intolerance or for whom it would be inappropriate to continue treatment with conventional agents. We estimated the efficacy and treatment costs...

Descripción completa

Detalles Bibliográficos
Autores principales: Batticciotto, Alberto, Ravasio, Roberto, Riva, Marta, Sarzi-Puttini, Piercarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969317/
https://www.ncbi.nlm.nih.gov/pubmed/27376373
http://dx.doi.org/10.1007/s12325-016-0372-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969317/
https://www.ncbi.nlm.nih.gov/pubmed/27376373
http://dx.doi.org/10.1007/s12325-016-0372-z

Ejemplares similares